
11 Octopus AIM VCT plc – Annual report and financial statements 2026
Performance
After adding back dividends of 5.0p paid during the year, the
NAV total return was up 2.4%, an encouraging recovery from
the decline reported in the half year results. This compares to
an increase of 18.6% in the FTSE AIM All Share Index, 27.0%
in the FTSE SmallCap (excluding investment companies),
and 27.3% in the FTSE All Share Index. Investor sentiment
remained cautious toward smaller high-growth companies.
The portfolio’s limited exposure to mining and financials, two
of the strongest sectors over the period and typically outside
VCT qualifying criteria, further contributed to the relative
divergence. AIM’s strongest sector last year was natural
resources, particularly mining and oil and gas, as investors
were drawn to commodity exposure and a steady flow of
positive news driven by high commodity price. The FTSE All-
Share benefited from broader sector strength led by major
banks, pharmaceuticals and defence which are predominantly
represented in the FTSE 100, alongside contributions from
industrial services in the FTSE SmallCap index.
Portfolio review
The Company’s well-diversified portfolio of established holdings
continues to provide resilience. During the period, positive
contributions came principally from Aurrigo International,
Gear4music, Applied Nutrition, Idox and Haydale, each
of which delivered supportive operational or commercial
progress. Aurrigo benefited from strong momentum driven
by global demand for its autonomous airside solutions and
new contract wins, while the launch of AutoCargo opened
an additional and potentially attractive growth avenue.
Encouragingly, the company raised £14.1 million in August
last year with support from new and existing investors.
The proceeds will help the company scale its autonomous
airport technology business by expanding its engineering and
deployment capability, building demonstrator vehicles and
preparing for larger manufacturing capacity. Gear4music
improved profitability through operational efficiencies,
disciplined inventory management, stable demand and
strengthening gross margins. Applied Nutrition continued
to perform well, supported by the strength of its brand and
growth across its product range, while Idox contributed
positively through steady trading and continued operational
execution. In October last year, Idox agreed a recommended
cash offer from Frankel UK Bidco Limited, a vehicle indirectly
owned by funds managed by Long Path Partners, at 71.5p
per share in cash, valuing the company at approximately
£340 million. The transaction is now complete. Haydale also
advanced commercially, with its JustHeat range securing
pilot deployments, UL certification for sales into the US and
Canada, and a number of contract wins that underpinned
positive valuation momentum.
Offsetting these gains, the main detractors were Strip
Tinning, Enteq Technologies, Feedback, Diaceutics and
Netcall. Strip Tinning’s performance was affected by weaker
sentiment and a more cautious market backdrop, while Enteq
Technologies remained challenged by subdued progress
in its market and commercial development. Feedback’s
shares came under pressure despite continued progress in
expanding its commercial opportunity. The business has
experienced disruption linked to changes in NHS funding
amid broader healthcare reforms, although conditions
now appear to be stabilising. Bleepa, the company’s main
technology, a clinical communication platform enabling the
secure sharing of patient data and medical images, remains
well aligned with NHS priorities around improving efficiency
and increasing investment in digital infrastructure, with
a growing number of trials underway across the country.
Diaceutics was impacted by softer momentum in its end
markets. However, the company continues to strengthen
its strategic positioning, now partnering with 18 of the top
20 global pharmaceutical companies. It expects to deliver
strong revenue growth this year, supported by accelerating
adoption of precision medicine, ongoing enhancements to
the DXRX platform, and expansion into new therapeutic
areas. The investment case remains compelling. Netcall,
despite continuing to trade well across its automation and
customer engagement platforms, was also a detractor over
the period, reflecting the market’s uneven response to its
valuation and near-term share price performance.
Non-qualifying investments are used to manage liquidity
while awaiting new qualifying investment opportunities
and we continue to hold some existing non-qualifying AIM
holdings where we see the opportunity for further share price
progress. During the year we increased our holdings in the FP
Octopus Future Generations Fund, investing a total of
£0.5 million over the period, and disposed of part of our holding
in FP Octopus UK Multi Cap Income Fund for £1.3 million and
FP Octopus UK Micro Cap Growth Fund for £1.4 million.
Unquoted investments
Hasgrove’s valuation increased materially during the year,
driven by consistent operational performance and a bid
approach from Castik Capital. The transaction, which
completed in January, valued the business at approximately
7x ARR and delivered a profit in excess of £9.5 million for the
Company, an excellent outcome reflective of our long-term
investment approach. Popsa continued to scale effectively,
reaching 2.5 million customers in 2025 and delivering strong
revenue growth. International expansion remains a core
driver, and the company’s valuation was adjusted upward
over the period reflecting this.
Investment Manager’s review continued